Biohit Oyj — Remuneration Information 2016

Feb 22, 2016

Disclosure 330603

Biohit Oyj - Company Announcement

Biohit Oyj’s Option Scheme I 2013 – International Sales Management Option Arrangement

Biohit Oyj Stock Exchange Release February 22, 2016 at 5:00 pm local time (EET) Biohit Oyj’s Board of Directors has decided to distribute in total 10,000 pcs option rights in class I 2013E of the option scheme I 2013 to the key members of the company’s international sales management as follows: Ilari Patrakka 5,000 pcs, Qiongchao Zhang 5,000 pcs. Each option right entitles its holder to subscribe for one (1) of the company’s new class B-shares. Share subscription price is 2.2766 euros. The subscription price can be amended pursuant to the terms and conditions of the option scheme. For option rights in class I 2013E share subscription period commences on June 1, 2018 and ends on May 31, 2019. The updated terms of the Biohit Oyj’s option schemes I 2013 and II 2013: http://www.biohithealthcare.com/investors/corporate-governance/biohit-oyj-s-opti o-schemes-i-2013-and-ii-2013 Additional information: CEO Semi Korpela, Biohit Oyj tel. +358 9 773 861 investor.relations@biohit.fi www.biohithealthcare.com Biohit in brief Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com